{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:09:30Z","timestamp":1790291370098,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12933-017-0548-0","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T09:21:00Z","timestamp":1495185660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The use of lipid-lowering therapy and effects of antihyperglycaemic therapy on lipids in subjects with type 2 diabetes with or without cardiovascular disease: a pooled analysis of data from eleven randomized trials with insulin glargine 100\u00a0U\/mL"],"prefix":"10.1186","volume":"16","author":[{"given":"Markolf","family":"Hanefeld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Traylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Landgraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,19]]},"reference":[{"key":"548_CR1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/qjmed\/hcp065","volume":"102","author":"M Miller","year":"2009","unstructured":"Miller M. Dyslipidemia and cardiovascular risk: the importance of early prevention. QJM. 2009;102:657\u201367.","journal-title":"QJM"},{"key":"548_CR2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pop.2012.11.003","volume":"40","author":"RH Nelson","year":"2013","unstructured":"Nelson RH. Hyperlipidemia as a risk factor for cardiovascular disease. Prim Care. 2013;40:195\u2013211.","journal-title":"Prim Care"},{"key":"548_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13300-014-0091-x","volume":"5","author":"G Dailey","year":"2014","unstructured":"Dailey G, Wang E. A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. Diabetes Ther. 2014;5:385\u2013402.","journal-title":"Diabetes Ther"},{"key":"548_CR4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","volume":"348","author":"P Gaede","year":"2003","unstructured":"Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383\u201393.","journal-title":"N Engl J Med"},{"key":"548_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"548_CR6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","volume":"352","author":"UK Prospective Diabetes Study (UKPDS) Group","year":"1998","unstructured":"UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33. Lancet. 1998;352:837\u201353.","journal-title":"Lancet"},{"key":"548_CR7","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","volume":"358","author":"HC Gerstein","year":"2008","unstructured":"Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Action to control cardiovascular risk in diabetes study group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545\u201359.","journal-title":"N Engl J Med"},{"key":"548_CR8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","volume":"38","author":"SE Inzucchi","year":"2015","unstructured":"Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140\u20139.","journal-title":"Diabetes Care"},{"key":"548_CR9","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"548_CR10","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"548_CR11","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1001\/archinte.164.19.2097","volume":"164","author":"E Chiquette","year":"2004","unstructured":"Chiquette E, Ramirez G, DeFronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164:2097\u2013104.","journal-title":"Arch Intern Med"},{"key":"548_CR12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","volume":"25","author":"M Hanefeld","year":"2004","unstructured":"Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10\u20136.","journal-title":"Eur Heart J"},{"issue":"Suppl 2","key":"548_CR13","doi-asserted-by":"crossref","first-page":"S342","DOI":"10.2337\/dc09-S336","volume":"32","author":"C Bianchi","year":"2009","unstructured":"Bianchi C, Miccoli R, Daniele G, Penno G, Del Prato S. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity\/mortality? Yes. Diabetes Care. 2009;32(Suppl 2):S342\u20138.","journal-title":"Yes. Diabetes Care."},{"key":"548_CR14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3121\/cmr.2010.898","volume":"9","author":"S Poonuru","year":"2011","unstructured":"Poonuru S, Pathak SR, Vats HS, Pathak RD. Rapid reduction of severely elevated serum triglycerides with insulin infusion, Gemfibrozil and Niacin. Clin Med Res. 2011;9:38\u201341.","journal-title":"Clin Med Res"},{"key":"548_CR15","first-page":"109","volume":"60","author":"CDC","year":"2011","unstructured":"CDC. Vital signs: prevalence, treatment, and control of high levels of low-density lipoprotein cholesterol. United States, 1999\u20132002 and 2005\u20132008. MMWR. 2011;60:109\u201314.","journal-title":"MMWR"},{"issue":"6","key":"548_CR16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1177\/1479164113496828","volume":"10","author":"ND Wong","year":"2013","unstructured":"Wong ND, Patao C, Wong K, Malik S, Franklin SS, Iloeje U. Trends in control of cardiovascular risk factors among US adults with type 2 diabetes from 1999 to 2010: comparison by prevalent cardiovascular disease status. Diabetes Vasc Dis Res. 2013;10(6):505\u201313.","journal-title":"Diabetes Vasc Dis Res"},{"key":"548_CR17","unstructured":"National Institute of Health (NIH). Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) executive summary. 2001. \n                        http:\/\/www.nhlbi.nih.gov\/files\/docs\/guidelines\/atp3xsum.pdf\n                        \n                    . Accessed 19 Jan 2016."},{"key":"548_CR18","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2337\/diaclin.26.1.3","volume":"26","author":"AL Peters","year":"2008","unstructured":"Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes. 2008;26:3\u20137.","journal-title":"Clin Diabetes"},{"issue":"25 Suppl 2","key":"548_CR19","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"NJ Stone","year":"2014","unstructured":"Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1\u201345.","journal-title":"Circulation"},{"issue":"25 Suppl 2","key":"548_CR20","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1161\/01.cir.0000437741.48606.98","volume":"129","author":"DC Goff Jr","year":"2014","unstructured":"Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D\u2019Agostino RB, Gibbons R, et al. 2013 ACC\/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S49\u201373.","journal-title":"Circulation"},{"key":"548_CR21","unstructured":"American College of Cardiology\/American Heart Association (ACC\/AHA). ASCVD Risk Estimator. 2014. \n                        http:\/\/tools.acc.org\/ASCVD-Risk-Estimator\/\n                        \n                    . Accessed 19 Jan 2016."},{"issue":"suppl 1","key":"548_CR22","first-page":"S1","volume":"39","author":"American Diabetes Association","year":"2016","unstructured":"American Diabetes Association. Standards of medical care in diabetes\u20142016. Diabetes Care. 2016;39(suppl 1):S1\u2013106.","journal-title":"Diabetes Care"},{"key":"548_CR23","doi-asserted-by":"crossref","first-page":"e001800","DOI":"10.1161\/JAHA.112.001800","volume":"1","author":"PH Jones","year":"2012","unstructured":"Jones PH, Nair R, Thakker KM. Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis. J Am Heart Assoc. 2012;1:e001800.","journal-title":"J Am Heart Assoc"},{"key":"548_CR24","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12933-015-0296-y","volume":"14","author":"V Gyberg","year":"2015","unstructured":"Gyberg V, De Bacquer D, De Backer G, Jennings C, Kotseva K, Mellbin L, et al. Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the Euro Observational Research Programme of the European Society of Cardiology. Cardiovasc Diabetol. 2015;14:133.","journal-title":"Cardiovasc Diabetol"},{"key":"548_CR25","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1001\/archinternmed.2009.318","volume":"169","author":"A Towfighi","year":"2009","unstructured":"Towfighi A, Zheng L, Ovbiagele B. Sex-specific trends in midlife coronary heart disease risk and prevalence. Arch Intern Med. 2009;169:1762\u20136.","journal-title":"Arch Intern Med"},{"key":"548_CR26","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2337\/diacare.27.3.704","volume":"27","author":"CS Fox","year":"2004","unstructured":"Fox CS, Sullivan L, D\u2019Agostino RB Sr, Wilson PW. Framingham heart study. The significant effect of diabetes duration on coronary heart disease mortality: the Framingham heart study. Diabetes Care. 2004;27:704\u20138.","journal-title":"Diabetes Care"},{"key":"548_CR27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1007\/s12471-010-0841-y","volume":"18","author":"AHEM Maas","year":"2010","unstructured":"Maas AHEM, Appelman YEA. Gender differences in coronary heart disease. Neth Heart J. 2010;18:598\u2013602.","journal-title":"Neth Heart J"},{"key":"548_CR28","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1093\/eurheartj\/ehi171","volume":"26","author":"CA Daly","year":"2005","unstructured":"Daly CA, Clemens F, Sendon JL, Tavazzi L, Boersma E, Danchin N, et al. The clinical characteristics and investigations planned in patients with stable angina presenting to cardiologists in Europe: from the Euro Heart Survey of Stable Angina. Eur Heart J. 2005;26:996\u20131010.","journal-title":"Eur Heart J"},{"issue":"1","key":"548_CR29","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00125-010-1918-2","volume":"54","author":"R Borg","year":"2011","unstructured":"Borg R, Kuenen JC, Carstensen B, Zheng H, Nathan DM, Heine RJ, et al. HbA1c and mean blood glucose show stronger associations with cardiovascular disease risk factors than do postprandial glycemia or glucose variability in persons with diabetes: the A1C-Derived Average Glucose (ADAG) study. Diabetologia. 2011;54(1):69\u201372.","journal-title":"Diabetologia"},{"key":"548_CR30","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2796.2010.02265.x","volume":"268","author":"K Eeg-Olofsson","year":"2010","unstructured":"Eeg-Olofsson K, Cederholm J, Nilsson PM, Zethelius B, Svensson AM, Gudbj\u00f6rnsd\u00f3ttir S, et al. New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes: an observational study from the Swedish National Diabetes Register (NDR). J Intern Med. 2010;268:471\u201382.","journal-title":"J Intern Med"},{"key":"548_CR31","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1462-8902.2004.00354.x","volume":"6","author":"TA Jacobson","year":"2004","unstructured":"Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JC, et al. Characteristics of US adults with the metabolic syndrome and therapeutic implications. Diabetes Obes Metab. 2004;6:353\u201362.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"548_CR32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/03007995.2015.1120715","volume":"32","author":"AK Gitt","year":"2016","unstructured":"Gitt AK, Sonntag F, Jannowitz C, Weizel A, Karmann B, Schaefer JR, Pittrow D, Hildemann SK. Better lipid target achievement for secondary prevention through disease management programs for diabetes mellitus and coronary heart disease in clinical practice in Germany. Curr Med Res Opin. 2016;32(3):417\u201326.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"548_CR33","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.annepidem.2014.05.001","volume":"24","author":"HK Wong","year":"2014","unstructured":"Wong HK, Ong KL, Cheung CL, Cheung BM. Utilization of glucose, blood pressure, and lipid lowering medications among people with type II diabetes in the United States, 1999\u20132010. Ann Epidemiol. 2014;24(7):516\u201321.","journal-title":"Ann Epidemiol"},{"issue":"14","key":"548_CR34","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12933-015-0191-6","volume":"26","author":"T Wang","year":"2015","unstructured":"Wang T, Xu Y, Xu M, Wang W, Bi Y, Lu J, Dai M, Zhang D, Ding L, Xu B, Sun J, Zhao W, Jiang Y, Wang L, Li Y, Zhang M, Lai S, Wang L, Ning G. Awareness, treatment and control of cardiometabolic disorders in Chinese adults with diabetes: a national representative population study. Cardiovasc Diabetol. 2015;26(14):28.","journal-title":"Cardiovasc Diabetol"},{"key":"548_CR35","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1016\/S0140-6736(12)60439-5","volume":"379","author":"P Aschner","year":"2012","unstructured":"Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012;379:2262\u20139.","journal-title":"Lancet"},{"key":"548_CR36","doi-asserted-by":"crossref","first-page":"588","DOI":"10.4158\/EP09281.OR","volume":"16","author":"LF Meneghini","year":"2010","unstructured":"Meneghini LF, Traylor L, Schwartz SL. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus. Endocr Pract. 2010;16:588\u201399.","journal-title":"Endocr Pract"},{"key":"548_CR37","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jdiacomp.2015.05.022","volume":"29","author":"P Hollander","year":"2015","unstructured":"Hollander P, Sugimoto D, Vlajnic A, Kilo C. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycaemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy. J Diabetes Complicat. 2015;29:1266\u201371.","journal-title":"J Diabetes Complicat"},{"key":"548_CR38","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.2337\/dc09-2294","volume":"33","author":"SG Swinnen","year":"2010","unstructured":"Swinnen SG, Dain MP, Aronson R, Davies M, Gerstein HC, Pfeiffer AF, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care. 2010;33:1176\u20138.","journal-title":"Diabetes Care"},{"key":"548_CR39","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1464-5491.2006.01881.x","volume":"23","author":"HF Gerstein","year":"2006","unstructured":"Gerstein HF, Yale J-F, Harris SB, Issa M, Stewart J, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and\/or sulphonylureas. The Canadian INSIGHT (implementing new strategies with insulin glargine for hyperglycaemia treatment) study. Diabet Med. 2006;23:736\u201342.","journal-title":"Diabet Med"},{"issue":"12","key":"548_CR40","doi-asserted-by":"crossref","first-page":"952","DOI":"10.7326\/0003-4819-138-12-200306170-00006","volume":"138","author":"A Fritsche","year":"2003","unstructured":"Fritsche A, Schweitzer MA, H\u00e4ring HU, 4001 Study Group. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med. 2003;138(12):952\u20139.","journal-title":"Ann Intern Med"},{"key":"548_CR41","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.arcmed.2005.10.015","volume":"37","author":"FG Eliaschewitz","year":"2006","unstructured":"Eliaschewitz FG, Calvo C, Valbuena H, Ruiz M, Aschner P, Villena J, et al. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride. Arch Med Res. 2006;37:495\u2013501.","journal-title":"Arch Med Res"},{"key":"548_CR42","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","volume":"26","author":"MC Riddle","year":"2003","unstructured":"Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080\u20136.","journal-title":"Diabetes Care"},{"key":"548_CR43","doi-asserted-by":"crossref","first-page":"554","DOI":"10.2337\/diacare.29.03.06.dc05-0695","volume":"29","author":"J Rosenstock","year":"2006","unstructured":"Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care. 2006;29:554\u20139.","journal-title":"Diabetes Care"},{"key":"548_CR44","unstructured":"HOE901_4021 [data on file]. ClinicalTrials.gov Identifier: NCT01336751."},{"key":"548_CR45","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.2337\/dc06-1357","volume":"30","author":"H Yki-J\u00e4rvinen","year":"2007","unstructured":"Yki-J\u00e4rvinen H, Juurinen L, Alvarsson M, Bystedt T, Caldwell I, Davies M, et al. Initiate insulin by aggressive titration and education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. Diabetes Care. 2007;30:1364\u20139.","journal-title":"Diabetes Care"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-017-0548-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T09:21:17Z","timestamp":1495185677000},"score":1,"resource":{"primary":{"URL":"http:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-017-0548-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,19]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["548"],"URL":"https:\/\/doi.org\/10.1186\/s12933-017-0548-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,19]]},"article-number":"66"}}